Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Apomorphine induced cognitive changes in Parkinson's disease

E Růzicka1, J Roth, N Spacková

  • 1Clinic of Neurology, 1st Medical Faculty, Charles University, Prague, Czech Republic.

Journal of Neurology, Neurosurgery, and Psychiatry
|August 1, 1994
PubMed
Summary

Apomorphine improves motor function in Parkinson's disease but slows cognitive processing, delaying auditory event-related potentials (ERPs) and impairing visuospatial skills.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring glymphatic system alterations in iRBD and Parkinson's disease using automated DTI-ALPS analysis.

NPJ Parkinson's disease·2025
Same author

Analysis of striatal connectivity corresponding to striosomes and matrix in de novo Parkinson's disease and isolated REM behavior disorder.

NPJ Parkinson's disease·2024
Same author

Comparative study of the substantia nigra echogenicity and <sup>123</sup>I-Ioflupane SPECT in patients with synucleinopathies with and without REM sleep behavior disorder.

Sleep medicine·2020
Same author

Comment on "pro-saccades predict cognitive decline in Parkinson's disease: ICICLE-PD".

Movement disorders : official journal of the Movement Disorder Society·2020
Same author

Automatic substantia nigra segmentation in neuromelanin-sensitive MRI by deep neural network in patients with prodromal and manifest synucleinopathy.

Physiological research·2020
Same author

Correction to: Pupillometry as an indicator of L-DOPA dosages in Parkinson's disease patients.

Journal of neural transmission (Vienna, Austria : 1996)·2018

Area of Science:

  • Neuroscience
  • Clinical Neurology
  • Psychopharmacology

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder affecting motor control.
  • Apomorphine is a dopamine agonist used to treat PD motor fluctuations.
  • Cognitive impairments are common in PD, but treatment effects on cognition are not fully understood.

Purpose of the Study:

  • To investigate the effects of a single apomorphine dose on cognitive processing in Parkinson's disease patients.
  • To examine changes in auditory event-related potentials (ERPs) and visual evoked potentials (VEPs) following apomorphine administration.
  • To correlate electrophysiological changes with behavioral measures of cognitive function.

Main Methods:

  • Auditory ERPs and VEPs were recorded in 8 PD patients before and after a single apomorphine dose.

Related Experiment Videos

  • Patients underwent motor assessments, the Benton Visual Retention Test (BVRT), and digit span tests.
  • Changes in ERP latencies, N2-P3 amplitude, and behavioral test performance were analyzed.

    • Main Results:

    • Apomorphine improved motor performance but significantly delayed ERP latencies and reduced N2-P3 amplitude.
    • Visuospatial perception, assessed by BVRT rotation errors, was impaired post-apomorphine.
    • Digit span test performance changes were also noted, suggesting broader cognitive effects.

    Conclusions:

    • Apomorphine, while beneficial for motor symptoms in PD, can negatively impact cognitive processing speed.
    • Electrophysiological findings suggest a slowing of central nervous system processing.
    • Apomorphine may induce visuospatial and other cognitive deficits, potentially mediated by dopamine autoreceptor stimulation.